Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study

International Journal of Hematology

Volumn 96, Issue 1, 2012, Pages 84-93

  Wakita, Atsushi ^a   Ohtake, Shigeki ^b   Takada, Satoru ^c   Yagasaki, Fumiharu ^d   Komatsu, Hirokazu ^e   Miyazaki, Yasushi ^f   Kubo, Kohmei ^g   Kimura, Yukihiko ^h   Takeshita, Akihiro ⁱ   Adachi, Yoko ^j   Kiyoi, Hitoshi ^k   Yamaguchi, Takuhiro ^l   Yoshida, Minoru ^m   Ohnishi, Kazunori ⁱ   Miyawaki, Shuichi ⁿ   Naoe, Tomoki ^k   Ueda, Ryuzo ^e   Ohno, Ryuzo ^o  

^a Nagoya City University West Medical Center   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j Kobe Central Hospital of Insurance   (Japan)

^k NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^o AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; Behenoyl cytarabine (enocitabine; BHAC); Daunorubicin; Elderly; Response oriented individualized induction therapy

Indexed keywords

ACLARUBICIN; BEHENOYL CYTARABINE; BESTATIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FIXED SCHEDULED INDUCTION THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESPONSE ORIENTED INDIVIDUALIZED INDUCTION THERAPY; SEX DIFFERENCE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUCINE; LEUKEMIA, MYELOID, ACUTE; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865044796     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1105-y     Document Type: Article

References (27)

1. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-76. (Pubitemid 29517929)
2. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-20.
3. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-8.
4. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-5.
5. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908-15. (Pubitemid 46854425)
6. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.
7. Uzuka Y, Liong SK, Yamagata S. Treatment of adult acute nonlymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy. Tohoku J Exp Med. 1976;118(Suppl):217-25.
8. Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, et al. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol. 1986;4:1740-7. (Pubitemid 17226662)
9. Ohno R, Kobayashi T, Morishima Y, Hiraoka A, Imai K, Asoh N, et al. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). Leukemia. 1992;6(Suppl 2):92-5.
10. Miyawaki S, Kobayashi T, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. Int J Hematol. 1999;70:56-7.
11. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSGAML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999;70:97-104.
12. Ohno R. How high can we increase complete remission rate in adult acute myeloid leukemia? Int J Hematol. 2000;72:272-9.
13. Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991;78:2520-6.
14. Zittoun R, Jehn U, Fiere D, Haanen C, Lowenberg B, Willemze R, et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood. 1989;73:896-906. (Pubitemid 19078365)
15. Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, et al. Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol. 2010;91:276-83.
16. Mathe G. Bestatin, an aminopeptidase inhibitor with a multipharmacological function. Biomed Pharmacother. 1991;45: 49-54.
17. Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother. 1986;23:5-10. (Pubitemid 16018442)
18. Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N. Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol. 1993;67:63-6. (Pubitemid 23246571)
19. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92: 2322-33. (Pubitemid 28452973)
20. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982;3:345-53. (Pubitemid 13113168)
21. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Dohner H, Gratwohl A, Pabst T, Verhoef G, Dutch-Belgian Cooperative Trial Group for Hemato- Oncology (HOVON), German AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235-48.
22. Abe F, Shibuya K, Uchida M, Takahashi K, Horinishi H, Matsuda A, et al. Effect of bestatin on syngeneic tumors in mice. Gann. 1984;75:89-94. (Pubitemid 14187355)
23. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, et al. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res. 1986;46:4505-10. (Pubitemid 16046879)
24. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26:88-130. (Pubitemid 43986471)
25. Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/ intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol. 1996;14:204-13.
26. Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS, Paietta E, et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 1997;80:2205-9. (Pubitemid 27509592)
27. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971-8.